Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Article 2024 en
Authors
JS
Jenny Sprooten
IV
Isaure Vanmeerbeek
AD
Angeliki Datsi
Abstract
1 min read
Current immunotherapies provide limited benefits against T cell-depleted tumors, calling for therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a type I interferon (IFN) response
Jenny Sprooten, Isaure Vanmeerbeek, Angeliki Datsi, Jannes Govaerts, Daniel Borràs, Stefan Naulaerts, Raquel S. Laureano, Anna Calvet, Marc Kuballa, Michael Sabel, Marion Rapp, Christiane B. Knobbe‐Thomsen, Peng Liu, Liwei Zhao, Oliver Kepp, Guido Guido Kroemer, Louis Boon, Sabine Tejpar, Jannie Borst, Susan Schlenner, Steven De Vleeschouwer, Rüdiger V. Sorg, Abhishek D. Garg
Mélanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Annamaria Kauzlaric, Krisztián Homicskó, Laura Codarri Deak, Pablo Umaña, Christian Klein, Douglas Hanahan
Discussion(0)
No comments yet. Be the first to comment.